Subscribe to Search results

A book titled "Haemophilic Bleeding: Early Management at Home", written by Dr. Aronstam, was published.

Published on:

Dr Aronstam reported that Treloars "had stopped recording the batch numbers of the transfusions because of the enormous amount of work this entailed".

Published on:

WHO recommended record keeping to help to control serum Hepatitis, including the batch numbers of blood products used for patients.

Published on:

It was reported that a minute fraction of a millilitre of virus-laden blood was sufficient to cause hepatitis. The production of large-pool plasma was abandoned as a result of this.

Published on:

Dr Biggs suggested that it was not yet proved that commercial Factor 8 was much more dangerous in causing hepatitis than other preparations.

Published on:

Dr Craske stated that NHS Concentrate was likely to be safer than commercial concentrate when it was available.

Published on:

Dr Arblaster stated several boys had withdrawn from the trial of prophylactic therapy with Factor 8 at Alton for various reasons.

Published on:

The second of three trials of prophylactic therapy at Treloar's studied twice weekly prophylactic therapy in Haemophilia A.

Published on:

The third of three trials of prophylactic therapy at Treloar's studied transfusion requirements of adolescents with severe Haemophilia A (1976-77)

Published on:

Dr Aronstam reported to the MRC that "We have now gone as far as we can with this trial, in the face of, I may say, enormous difficulties which I feel were a direct result of using a placebo for this study."'

Published on:

A report, "Prophylaxis in Haemophilia: A Double-blind Controlled Trial", was published in the British Journal of Haematology, recording the results of a trial of prophylactic Factor 8 treatment which was carried out at the Lord Mayor Treloar College.

Published on:

At a meeting of Haemophilia Centre Directors it was agreed that a controlled trial of prophylactic Factor 8 therapy would be useful.

Published on:

The UKHCDO discussed the proposal for a prophylaxis trial. Conducting such a trial was seen as problematic and Dr Biggs stated that the only place where it could be carried out in the UK was the Lord Mayor Treloar College.

Published on:

At a UKHCDO meeting a potential trial of prophylactic treatment was discussed and it was stated that they would only be able to undertake the trial at the Lord Mayor Treloar College.

Published on:

It was suggested that trials were possible at Treloar's due to the fact that the boys were under close daily observation for prolonged periods.

Published on:

The protocol for the Double-blind Controlled Trial of Prophylactic treatment at Treloars stated that half the children would only get a low dose in order for the trial to be effective.

Published on:

A proposal was submitted for a trial of prophylactic administration of cryoprecipitate at Treloars.

Published on:

Dr Aronstam sought a clinical trial exemption certificate to permit him to administer Mono-V3:C, a product of Speywood Laboratories, to 50 pupils over a period of 8 months.

Published on:

The Committee on Safety of Medicines advised that the bulk cryoprecipitate was to be prepared by Alpha Therapeutic only from source plasma derived from their own licensed plasmapheresis centres. This was considered to be risky as the effects resulting from these products were uncertain.

Published on:

Due to a large research grant Treloar's was able to supply students with much more blood product than their home clinicians.

Published on: